November 29th-30th 2017

Invited Faculty

Paolo A. Ascierto
Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, National Cancer Institute "Fondazione G. Pascale" of Naples, Italy

Sergio Bracarda
Oncology Department Director - AUSL 8, Arezzo, Italy

Luigi Buonaguro
Unit of Molecular Biology and Viral Oncology, National Cancer Institute "Fondazione G. Pascale" of Naples, Italy

Lisa H. Butterfield
SITC, University of Pittsburgh, Pennsylvania, US

James Brugarolas
Director of the kidney cancer program, Associate Professor of Internal Medicine, Cancer Biology, Genetics, Development and Disease, UT Southwestern Medical Center, The University of Texas Southwestern Medical Center, Dallas, Texas, US

Fortunato Ciardiello
ESMO President - Full Professor of Medical Oncology, Head of the Laboratory of Experimental Therapeutics, Head of the Division of Medical Oncology, Seconda Università di Napoli, Naples, Italy

Bruno Daniele
Department Director of Oncology - U.O.C. of Medical Oncology, G. Rummo Hospital, Benevento, Italy

Alexander Eggermont
Institut de Cancèrologie Gustave Roussy, Villejuif, Paris-Sud, France

Robert J. Ferris
UPMC Endowed Professor and Chief, Division of Head and Neck Surgery, Department of Otolaryngolog, University of Pittsburgh, Pennsylvania, US

Bernard A. Fox
Chief of the Laboratory of Molecular and Tumor Immunology, Oregon Health and Science University, Providence Cancer Center, Portland Medical Center, Oregon

Jerome Galon
Research Director, National Institute of Health and Medical Research (INSERM), Paris, France

Omid Hamid
Chief, Translational Research and Immunotherapy, Director, Melanoma Therapeutics, The Angeles Clinic and Research Institute, Santa Monica, California, US

Matthew Hellman
Memorial Sloan Kettering Cancer Center, New York, New York, US

Roy Herbst
Ensign Professor of Medicine (Medical Oncology) and Professor of Pharmacology, Chief of Medical Oncology, Yale Cancer Center, New Haven

Carl June
Richard W. Vague Professor in Immunotherapy, Professor of Medicine, University of Pennsylvania, Perelman School of Medicine, Philadelphia, Pennsylvania, US

Howard Kaufman
Professor of Surgery, Robert Wood Johnson Medical School Rutgers, The State University of New Jersey, New Jersey, US

Mario Mandalà
Oncology Unit Director, Papa Giovanni XXII Hospital, Bergamo, Italy

Marco Merlano
Oncology Department Director AO S.Croce & Carle, Cuneo, Italy

Rita Nanda
Assistant Professor of Medicine, Associate Director, Breast Medical Oncology, The University of Chicago Medicine, Chicago

Paul Nathan
Consultant Medical Oncologist, Mount Vernon Cancer Centre

Crystal M. Paulos
SITC, Medical University of South Carolina, US

Sandro Pignata
Director of Uro-Gyncological Oncology Department, National Cancer Institute "Fondazione G. Pascale" of Naples, Italy

Igor Puzanov
Associate Professor of Medicine, Associate Director of Phase I Drug Development, Director, Melanoma Clinical Research, Director of Early Clinical Trials and Developmental Therapeutics, Director of Melanoma Program, Professor of Medicine and Oncology at Roswell Park Cancer Institute in Buffalo New York

Ryan J. Sullivan
Assistant Professor, Medicine, Harvard Medical School, Assistant Professor, Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts

Ena Wang
Division Chief of Translational Medicine, Sidra Medical and Research Centre, Doha, Qatar

Hassane Zarour
Professor of Medicine, Immunology and Dermatology, Co-Leader, Melanoma Program, Cancer Institute, University of Pittsburgh, Pennsylvania, US

Heinz Zwierzina
Chairman of the CDDF - Cancer Drug Development Forum and Professor of Internal Medicine at Innsbruck University in Austria

For information please contact info@melanomabridge.org